Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $6.8750.

Several equities research analysts recently commented on SRTS shares. Maxim Group cut their target price on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They set a “buy” rating and a $7.50 price target for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th.

Institutional Trading of Sensus Healthcare

Institutional investors have recently bought and sold shares of the company. Opes Wealth Management LLC acquired a new stake in shares of Sensus Healthcare during the 3rd quarter worth approximately $50,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the 4th quarter valued at $77,000. Jane Street Group LLC bought a new position in Sensus Healthcare during the fourth quarter worth $79,000. Mindset Wealth Management LLC boosted its stake in Sensus Healthcare by 28.1% during the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC acquired a new stake in Sensus Healthcare in the fourth quarter worth $219,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Performance

Sensus Healthcare stock opened at $3.98 on Friday. Sensus Healthcare has a 52 week low of $3.03 and a 52 week high of $5.92. The stock has a market capitalization of $65.51 million, a P/E ratio of -8.47 and a beta of 1.22. The stock has a fifty day moving average of $4.36 and a 200-day moving average of $3.99.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, February 12th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The company had revenue of $4.94 million during the quarter, compared to the consensus estimate of $8.35 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%. On average, research analysts forecast that Sensus Healthcare will post 0.32 earnings per share for the current year.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.